This company listing is no longer active
IMV Resultados de beneficios anteriores
Pasado controles de criterios 0/6
IMV's earnings have been declining at an average annual rate of -26%, while the Biotechs industry saw earnings growing at 32.7% annually. Revenues have been declining at an average rate of 52.1% per year.
Información clave
-26.0%
Tasa de crecimiento de los beneficios
-10.6%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 51.1% |
| Tasa de crecimiento de los ingresos | -52.1% |
| Rentabilidad financiera | n/a |
| Margen neto | n/a |
| Última actualización de beneficios | 31 Dec 2022 |
Actualizaciones de resultados anteriores recientes
Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero IMV. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -38 | 17 | 0 |
| 30 Sep 22 | 0 | -41 | 17 | 0 |
| 30 Jun 22 | 0 | -43 | 18 | 0 |
| 31 Mar 22 | 0 | -40 | 17 | 0 |
| 31 Dec 21 | 0 | -37 | 16 | 0 |
| 30 Sep 21 | 0 | -32 | 15 | 0 |
| 30 Jun 21 | 0 | -28 | 13 | 0 |
| 31 Mar 21 | 0 | -26 | 12 | 0 |
| 31 Dec 20 | 0 | -26 | 11 | 0 |
| 30 Sep 20 | 0 | -25 | 10 | 0 |
| 30 Jun 20 | 0 | -24 | 9 | 0 |
| 31 Mar 20 | 0 | -22 | 8 | 0 |
| 31 Dec 19 | 0 | -21 | 8 | 0 |
| 30 Sep 19 | 0 | -20 | 7 | 0 |
| 30 Jun 19 | 0 | -19 | 7 | 0 |
| 31 Mar 19 | 0 | -19 | 7 | 0 |
| 31 Dec 18 | 0 | -16 | 7 | 0 |
| 30 Sep 18 | 0 | -15 | 7 | 0 |
| 30 Jun 18 | 0 | -12 | 6 | 0 |
| 31 Mar 18 | 0 | -10 | 5 | 0 |
| 31 Dec 17 | 0 | -10 | 5 | 0 |
| 30 Sep 17 | 0 | -9 | 4 | 0 |
| 30 Jun 17 | 0 | -8 | 4 | -1 |
| 31 Mar 17 | 0 | -7 | 3 | -1 |
| 31 Dec 16 | 0 | -7 | 3 | 0 |
| 30 Sep 16 | 0 | -6 | 3 | 1 |
| 30 Jun 16 | 0 | -6 | 3 | 3 |
| 31 Mar 16 | 0 | -7 | 3 | 4 |
| 31 Dec 15 | 0 | -6 | 3 | 3 |
| 30 Sep 15 | 0 | -6 | 3 | 3 |
| 30 Jun 15 | 0 | -6 | 3 | 3 |
| 31 Mar 15 | 0 | -5 | 2 | 3 |
| 31 Dec 14 | 0 | -6 | 3 | 3 |
| 30 Sep 14 | 0 | -5 | 2 | 3 |
| 30 Jun 14 | 0 | -5 | 2 | 3 |
| 31 Mar 14 | 0 | -5 | 3 | 2 |
| 31 Dec 13 | 0 | -4 | 3 | 2 |
| 30 Sep 13 | 0 | -5 | 3 | 3 |
| 30 Jun 13 | 0 | -6 | 3 | 3 |
| 31 Mar 13 | 0 | -6 | 3 | 3 |
| 31 Dec 12 | 0 | -6 | 3 | 3 |
| 30 Sep 12 | 0 | -6 | 3 | 3 |
Ingresos de calidad: IMV is currently unprofitable.
Margen de beneficios creciente: IMV is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: IMV is unprofitable, and losses have increased over the past 5 years at a rate of 26% per year.
Acelerando crecimiento: Unable to compare IMV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: IMV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11%).
Rentabilidad financiera
Alta ROE: IMV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.